AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the a...
🔗 Read more: https://medicalxpress.com/news/2026-03-aaos-glp-receptor-agonist-year.html
#News #Medicine #Science
Edited
medicalxpress.com
AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the...
Comments
Log in to leave a comment.
No comments yet. Be the first to comment!